UC Clinical Pharmacy Practice

Research Interest Among Cancer Patients with Cognitive Problems

Daniella Chan¹, Ding Quan Ng¹, Munjal M. Acharya¹, Joshua Grill¹, Alexandre Chan¹ (1) University of California Irvine, Irvine, CA, USA

Introduction

Cancer-related cognitive impairment (CRCI) remains a significant unmet need. Continued participation from cancer patients with CRCI is necessary in generating quality data from observational and interventional studies. Understanding their research interest will help with designing feasible studies with good participation rates. <u>Thus, we</u> <u>evaluated research attitudes and willingness to participate in research</u> <u>among cancer patients with varying degree of cognitive function</u>.



Results

(1) CFI Scores & Sociodemographic Characteristics Table 1: Baseline characteristics pre-IPTW				
Variables	Non-CRCI (n = 909)	CRCI (n = 256)	Р	
CFI, mean (min, max)	1.61 (0.00, 4.00)	7.14 (4.08, 14.00)	-	
Age, mean (SD)	66.6 (11.4)	65.0 (13.4)	0.144	
Female, n (%)	545 (60.0)	163 (63.7)	0.310	
Non-Hispanic White , n (%)	758 (83.4)	191 (74.6)	0.001	
Education Years, mean (SD)	16.7 (2.5)	16.0 (3.0)	<0.001	

(2) Clinical Characteristics

More CRCI registrants self-reported past diagnoses of Alzheimer's disease, mild cognitive impairment, stroke, depression, post-traumatic stress disorder, alcohol abuse than non-CRCI (all P<0.05). There were less skin cancer cases in CRCI. We observed no difference in cancer treatment received (radiation, chemotherapy, surgery) and years since last treatment.

Discussion

• Cancer patients with cognitive problems may be more interested in studies involving approved medications.

 Lumbar puncture and brain donation as approaches to CRCI biomarker discovery could be considered for future research studies. (3) IPTW and outcomes

All propensity score-adjusted covariates achieved standardized mean differences of <0.1 after IPTW, indicating good covariate balance.

Table 2: Outcomes post-IPTW

Outcomes	Non-CRCI (n = 254.4)	CRCI (n = 896.5)	Р
RAQ, mean (SD)	29.0 (4.3)	28.7 (4.1)	0.460
WTP , n (%)			
Approved meds	221.9 (87.2)	827.3 (92.3)	0.030
Lumbar puncture	95.4 (37.5)	417.4 (46.6)	0.027
Autopsy	175.2 (68.9)	698.7 (77.9)	0.022

There was no difference in attitudes towards research between CRCI and non-CRCI registrants.

Yet, more CRCI registrants were interested in research studies investigating approved medications (92% vs 87%, P=0.030), involving lumbar puncture (47% vs 38%, P=0.027), and autopsy (78% vs 69%, P=0.022).

Acknowledgements

The authors would like to acknowledge all C2C registrants.

References

1. Grill JD, et al. J Alzheimers Dis. 2018;63(3):1055-1063.

2. UC Irvine Consent-to-Contact (C2C). https://c2c.uci.edu/

